New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
06:05 EDTCLVSClovis commences dosing of first patient in RUCAPANC study
Clovis announced that the RUCAPANC study has commenced with the dosing of the first patient at a U.S. study site. Rucaparib is the company’s oral, potent, small molecule poly polymerase inhibitor being developed for the treatment of pancreatic cancer and platinum-sensitive ovarian cancer.
News For CLVS From The Last 14 Days
Check below for free stories on CLVS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 8, 2014
06:44 EDTCLVSClovis October volatility elevated into updates
Subscribe for More Information
06:39 EDTCLVSClovis price target raised to $100 from $87 at Piper Jaffray
Piper Jaffray raised its price target for Clovis shares to $100 saying the company's clinical development programs are progressing well, with strong enrollment indicated for rociletinib and rucaparib trials. Piper reiterates an Overweight rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use